Skip to main content

Advertisement

Fig. 10 | Journal of Neuroinflammation

Fig. 10

From: Exosomes derived from atorvastatin-modified bone marrow dendritic cells ameliorate experimental autoimmune myasthenia gravis by up-regulated levels of IDO/Treg and partly dependent on FasL/Fas pathway

Fig. 10

Effects of statin-Dex blocked with anti-FasL antibody on the levels of anti-R97–116 peptide IgG antibody and its subtype. Serums in different time points (days 10, 21, 32, and 43 p.i.) were collected for detection. Statin-Dex with anti-FasL blocking antibody treatment resulted in higher levels of serum anti-R97–116 IgG and IgG2b antibodies on day 10 p.i., and lower level of IgG1 antibody on day 43 p.i. when compared with statin-Dex with isotype control antibody treatment. Each serum sample was tested in triplicate. All results are expressed as mean ± SD (n = 6 rats per group) (**p < 0.01)

Back to article page